Literature DB >> 17720068

Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac.

Eric J Wolf1, Alexandra Braunstein, Carolyn Shih, Richard E Braunstein.   

Abstract

PURPOSE: To compare the incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated postoperatively with topical prednisolone and those treated with topical prednisolone and nepafenac 0.1% suspension (Nevanac).
SETTING: Edward S. Harkness Eye Institute of Columbia University, New York, New York, USA.
METHODS: This retrospective chart review was of consecutive patients who had phacoemulsification at a single institute and were given topical prednisolone alone or topical prednisolone and nepafenac to prevent cystoid macular edema. Data collection included preexisting ocular and systemic diseases, concurrent use of ocular and systemic medications, surgical technique, intraoperative and postoperative complications, follow-up visual and ocular assessments, and postoperative optical coherence tomography (OCT) assessment for macular edema.
RESULTS: Postoperatively, 240 patients were treated with prednisolone and 210 patients, with prednisolone-nepafenac. Preoperatively, the 2 groups were demographically and clinically comparable in sex distribution (P = .8400), history of diabetes (P = .7267), hypertension or cardiac disease (P = .8690), and concurrent use of oral nonsteroidal anti-inflammatory drugs (P = .7303). Iris manipulation was done in 16 patients in the prednisolone-alone group and 10 patients in the prednisolone-nepafenac group (P = .3876). Capsule staining was done in 5 patients and 4 patients, respectively. All patients were followed for at least 1 month postoperatively. Visually significant pseudophakic macular edema was documented by OCT in 5 patients treated with prednisolone alone and in no patients treated with prednisolone and nepafenac (P = .0354). No significant intraoperative or postoperative complications were reported.
CONCLUSION: Patients treated with topical prednisolone alone had a significantly higher incidence of visually significant pseudophakic macular edema after uneventful cataract surgery than those treated with topical prednisolone and nepafenac.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720068     DOI: 10.1016/j.jcrs.2007.05.018

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  18 in total

Review 1.  Uveitic macular edema.

Authors:  C Fardeau; E Champion; N Massamba; P LeHoang
Journal:  Eye (Lond)       Date:  2016-06-03       Impact factor: 3.775

2.  Melatonin and amfenac modulate calcium entry, apoptosis, and oxidative stress in ARPE-19 cell culture exposed to blue light irradiation (405 nm).

Authors:  M Argun; L Tök; A C Uğuz; Ö Çelik; Ö Y Tök; M Naziroğlu
Journal:  Eye (Lond)       Date:  2014-03-07       Impact factor: 3.775

3.  Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.

Authors:  Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac.

Authors:  Guadalupe Cervantes-Coste; Yuriana G Sánchez-Castro; Mónica Orozco-Carroll; Erick Mendoza-Schuster; Cecilio Velasco-Barona
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

Review 7.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

8.  Etiology and treatment of the inflammatory causes of cystoid macular edema.

Authors:  Hyung Cho; Assumpta Madu
Journal:  J Inflamm Res       Date:  2009-10-02

9.  Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site.

Authors:  Melissa Cable
Journal:  Clin Ophthalmol       Date:  2012-07-02

10.  Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.

Authors:  Rishi Singh; Louis Alpern; Glenn J Jaffe; Robert P Lehmann; John Lim; Harvey J Reiser; Kenneth Sall; Thomas Walters; Dana Sager
Journal:  Clin Ophthalmol       Date:  2012-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.